Skip to main content

Table 1 Baseline characteristics of randomized study participants (ITT population)

From: Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children

Characteristics

ASAQ

AL

DHAP

P-value

Age* (months) ± SD

55.35 ± 34.5

57.97 ± 33.8

54.88 ± 32.9

0.67

Weight* (kg) ± SD

16.9 ± 7.3

17.8 ± 7.7

16.9 ± 6.8

0.41

Axillary temperature* (°C) ± SD

38 ± 1.1

38 ± 1.1

37.8 ± 1.1

0.5

Haemoglobin* (g/dl) ± SD

10.4 ± 2.14

9.9 ± 2.1

9.9 ± 2.1

0.44

Parasite density** (/μl)

13,555 (1,040-100,000)

14,808 (1,060-100,000)

13,690 (1,040-100,000)

0.71

Creatinine (mg/l)

0.65 ± 0.46

0.73 ± 1

0.68 ± 0.72

0.48

ALAT (IU/l)

30 ± 52

25 ± 23

26 ± 28

0.81

Absolute neutrophil count /μl

47 ± 18

48 ± 19

47 ± 18

0.76

Sex (male: female)

(145:131)

(67:75)

(142:137)

0.5

  1. * = mean ± SD (standard deviation); ** = median and range; ALAT = alanine aminotransferase.